Claims for Patent: 8,961,968

Summary for Patent: 8,961,968

Title:	Human monoclonal antibodies against CD25
Abstract:	Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Inventor(s):	Schuurman; Janine (Amsterdam, NL), Havenith; Catharina Emanuele Gerarda (Bodegraven, NL), Parren; Paul (Odyk, NL), Van De Winkel; Jan G. J. (Zeist, NL), Williams; Denise Leah (San Jose, CA), Petersen; Jorgen (Rungsted Ksyt, DK), Baadsgaard; Ole (Malmo, SE)
Assignee:	Genmab A/S (Copenhagen, DK)
Application Number:	13/465,181
Patent Claims:	1. A composition comprising an isolated human monoclonal antibody which binds to human CD25, comprises a heavy chain variable region and a light chain variable region, and inhibits IL-2 binding to CD25, and a pharmaceutically acceptable carrier, wherein the antibody is selected from the group consisting of: (a) an antibody wherein at least one variable region is selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, and 16; (b) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 6 and 8, respectively; (c) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 14 and 16, respectively; (d) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 2 and 4, respectively; (e) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 10 and 12, respectively; (f) an antibody comprising heavy or light chain CDR sequences set forth in SEQ ID NOs: 35, 36, 37 and SEQ ID NOs: 38, 39, 40, respectively; (g) an antibody comprising heavy and light chain CDR sequences set forth in SEQ ID NOs: 17, 18, 19 and SEQ ID NOs: 20, 21, 22, respectively; (h) an antibody comprising heavy and light chain CDR sequences set forth in SEQ ID NOs: 23, 24, 25 and SEQ ID NOs: 26, 27, 28, respectively; (i) an antibody comprising heavy and light chain CDR sequences set forth in SEQ ID NOs: 29, 30, 31 and SEQ ID NOs: 32, 33, 34, respectively; (j) an antibody which binds to an epitope on human CD25 defined by antibody (b), (c), (d) or (e); and (k) an antibody having the binding characteristics of antibody (b), (c), (d) or (e). 2. The composition of claim 1, further comprising a second therapeutic agent. 3. The composition of claim 2, wherein the therapeutic agent is an immunosuppressant selected from the group consisting of cyclosporine, azathioprine, mycophenolic acid, mycophenolate mofetil, a corticosteroid, methotrexate, gold salts, sulfasalazine, an antimalarial, brequinar, leflunomide, mizoribine, 15-deoxyspergualine, 6-mercaptopurine, cyclophosphamide, rapamycin, tacrolimus (FK-506), OKT3, and anti-thymocyte globulin. 4. The composition of claim 2, wherein the therapeutic agent is an anti-inflammatory agent selected from the group consisting of a steroidal drug, a NSAID (nonsteroidal anti-inflammatory drug), and a DMARD, hydroxychloroquine, sulfasalazine, leflunomide, an IL-1 receptor blocking agent, a TNF-.alpha. blocking agent, an anti-IL-6R antibody, CTLA4Ig, and an anti-IL-15 antibody. 5. The composition of claim 2, wherein the therapeutic agent is selected from the group consisting of coal tar, A vitamin, anthralin, calcipotrien, tarazotene, corticosteroids, methotrexate, a retinoid, cyclosporine, etanercept, alefacept, efaluzimab, 6-thioguanine, mycophenolate mofetil, tacrolimus (FK-506), hydroxyurea, doxorubicin, cisplatin, bleomycin, carmustine, chlorambucil, and cyclophosphamide. 6. An immunoconjugate comprising an isolated human monoclonal antibody which binds to human CD25, comprises a heavy chain variable region and a light chain variable region, and inhibits IL-2 binding to CD25, wherein the antibody is linked to a cytotoxic agent, a radioisotope, or a drug, and wherein the antibody is selected from the group consisting of: (a) an antibody wherein at least one variable region is selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, and 16; (b) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 6 and 8, respectively; (c) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 14 and 16, respectively; (d) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 2 and 4, respectively; (e) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 10 and 12, respectively; (f) an antibody comprising heavy or light chain CDR sequences set forth in SEQ ID NOs: 35, 36, 37 and SEQ ID NOs: 38, 39, 40, respectively; (g) an antibody comprising heavy and light chain CDR sequences set forth in SEQ ID NOs: 17, 18, 19 and SEQ ID NOs: 20, 21, 22, respectively; (h) an antibody comprising heavy and light chain CDR sequences set forth in SEQ ID NOs: 23, 24, 25 and SEQ ID NOs: 26, 27, 28, respectively; (i) an antibody comprising heavy and light chain CDR sequences set forth in SEQ ID NOs: 29, 30, 31 and SEQ ID NOs: 32, 33, 34, respectively; (j) an antibody which binds to an epitope on human CD25 defined by antibody (b), (c), (d) or (e); and (k) an antibody having the binding characteristics of antibody (b), (c), (d) or (e). 7. A bispecific or multispecific molecule comprising an isolated human monoclonal antibody which binds to human CD25, comprises a heavy chain variable region and a light chain variable region, and inhibits IL-2 binding to CD25, wherein the antibody is selected from the group consisting of: (a) an antibody wherein at least one variable region is selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, and 16; (b) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 6 and 8, respectively; (c) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 14 and 16, respectively; (d) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 2 and 4, respectively; (e) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 10 and 12, respectively; (f) an antibody comprising heavy or light chain CDR sequences set forth in SEQ ID NOs: 35, 36, 37 and SEQ ID NOs: 38, 39, 40, respectively; (g) an antibody comprising heavy and light chain CDR sequences set forth in SEQ ID NOs: 17, 18, 19 and SEQ ID NOs: 20, 21, 22, respectively; (h) an antibody comprising heavy and light chain CDR sequences set forth in SEQ ID NOs: 23, 24, 25 and SEQ ID NOs: 26, 27, 28, respectively; (i) an antibody comprising heavy and light chain CDR sequences set forth in SEQ ID NOs: 29, 30, 31 and SEQ ID NOs: 32, 33, 34, respectively; (j) an antibody which binds to an epitope on human CD25 defined by antibody (b), (c), (d) or (e); and (k) an antibody having the binding characteristics of antibody (b), (c), (d) or (e); and wherein the antibody is linked to a second binding specificity for CD3, CD4, IL-15R, membrane bound or receptor bound TNF-.alpha., or membrane bound or receptor bound IL-15. 8. A method for detecting the presence of CD25 antigen, or a cell expressing CD25, in a sample comprising: contacting the sample with an isolated human monoclonal antibody, which binds to human CD25, comprises a heavy chain variable region and a light chain variable region and inhibits IL-2 binding to CD25 under conditions that allow for formation of a complex between the antibody and CD25, wherein the antibody is selected from the group consisting of: (a) an antibody wherein at least one variable region is selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, and 16; (b) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 6 and 8, respectively; (c) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 14 and 16, respectively; (d) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 2 and 4, respectively; (e) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs: 10 and 12, respectively; (f) an antibody comprising heavy or light chain CDR sequences set forth in SEQ ID NOs: 35, 36, 37 and SEQ ID NOs: 38, 39, 40, respectively; (g) an antibody comprising heavy and light chain CDR sequences set forth in SEQ ID NOs: 17, 18, 19 and SEQ ID NOs: 20, 21, 22, respectively; (h) an antibody comprising heavy and light chain CDR sequences set forth in SEQ ID NOs: 23, 24, 25 and SEQ ID NOs: 26, 27, 28, respectively; (i) an antibody comprising heavy and light chain CDR sequences set forth in SEQ ID NOs: 29, 30, 31 and SEQ ID NOs: 32, 33, 34, respectively; (j) an antibody which binds to an epitope on human CD25 defined by antibody (b), (c), (d) or (e); and (k) an antibody having the binding characteristics of antibody (b), (c), (d) or (e); and detecting the formation of a complex.

Details for Patent 8,961,968

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2022-11-15
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2022-11-15
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2022-11-15
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2022-11-15
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017		2022-11-15
Immunex Corporation	ENBREL	etanercept	Injection	103795			2022-11-15
Immunex Corporation	ENBREL	etanercept	Injection	103795	03/05/2020		2022-11-15